Design Therapeutics, Inc.

NASDAQ:DSGN

Biotechnology

Healthcare
$9.47 +1.59%

+$0.19 today

Market cap
$606.42M
Beta
1.66
P/E (TTM)
-10.7
EPS (TTM)
-$1.13
52W Low $3.33High $17.25

Volume 0.32M

Average 0.74M

DSGN Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Design Therapeutics, Inc.NASDAQ: DSGN

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 6.6% from a year ago

Cash & equivalents stood at $12.77M at the end of Q1 FY2026, down 6.6% from a year earlier and down 24.2% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.

Context

  • Cash & equivalents amounted to 5.5% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -6.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.77M-24.2% QoQ
Last fiscal yearDec 2025
$16.86M-25.3% YoY
Year agoMar 2025
$13.67M-6.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.6%——
1 year-25.3%——
3-year CAGR-14.0%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
16.86M USD
Year-over-year change
-25.3%
4-year CAGR
-51.3%

Cash & Equivalents vs competitors

How DSGN compares with its peers on the latest reported figures

  • DSGN's Mar 2026 cash & equivalents of $12.77M is the lowest of the 11 companies compared; the peer median is $297.02M.
  • Its year-over-year change of -6.6% is the 9th highest of 11, against a peer median of +29.3%.
  • Cash & equivalents amounts to 5.5% of total assets for DSGN, versus a peer median of 33.7%.
DSGN Competitors Peer median
Cash & Equivalents for DSGN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PTCTPTC Therapeutics, Inc.Jun 2026$1.05B +3.2%+52.1%32.3%
DYNDyne Therapeutics, Inc.Jun 2026$676.11M +39.4%+73.1%68.0%
WVEWave Life Sciences Ltd.Mar 2026$544.59M +124.0%+89.5%93.3%
SRPTSarepta Therapeutics, Inc.Mar 2026$464.45M +92.8%-6.1%14.6%
SLDBSolid Biosciences Inc.Mar 2026$297.74M +41.4%-27.2%70.4%
IONSIonis Pharmaceuticals, Inc.Sep 2026$296.3M -12.4%+10.4%10.2%
LRMRLarimar Therapeutics, Inc.Mar 2026$177.91M +742.2%+47.1%85.3%
STOKStoke Therapeutics, Inc.Mar 2026$155.66M -43.4%-9.5%35.1%
FULCFulcrum Therapeutics, Inc.Mar 2026$50.26M +19.2%+77.9%14.5%
PEPGPepGen Inc.Mar 2026$42.15M -3.4%-30.7%27.0%
DSGNDesign Therapeutics, Inc.Mar 2026$12.77M -6.6%-14.0%5.5%
Peer median (excluding DSGN) $297.02M+29.3%+28.8%33.7%

Competitors are the stored peer set for DSGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents298.57M26.5M21.2M22.56M16.86M
Short-term Investments85.5M303.89M260.6M222.91M202.99M
Net Receivables110K1.12M1.43M1.26M1.68M
Inventory00000
Other Current Assets00000
Total Current Assets385.44M335.12M284.58M248.04M223.78M
Property, Plant & Equipment (Net)5.12M5.56M4.63M3.63M2.42M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets0459K430K427K0
Total Non-current Assets5.12M6.02M5.06M4.05M2.42M
Total Assets390.56M341.14M289.64M252.09M226.2M
Account Payables1.62M3.03M1.94M2.19M2.31M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities2.15M3.54M4.03M3.58M4.63M
Total Current Liabilities5.28M10.78M9.62M8.46M13.06M
Long-term Debt0000645K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities3.14M3.05M2.33M1.53M645K
Total Liabilities8.43M13.83M11.96M10M13.7M
Common Stock6K6K6K6K6K
Retained Earnings(47.46M)(110.76M)(177.63M)(227.21M)(297.01M)
Accumulated OCI(244K)(3.36M)62K475K403K
Other Stockholders Equity00000
Minority Interest00000
Total Equity382.13M327.31M277.69M242.1M212.5M
Total Debt3.63M3.69M3.05M2.33M1.54M
Net Debt(294.94M)(22.81M)(18.15M)(20.23M)(15.32M)

Design Therapeutics, Inc.

NASDAQ:DSGN

Intrinsic Alpha fair value

Locked

Current Price

$9.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.